Literature DB >> 18502305

Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies.

Theodore Mazzone1, Alan Chait, Jorge Plutzky.   

Abstract

Individuals with type 2 diabetes mellitus have increased cardiovascular disease risk compared with those without diabetes. Treatment of the residual risk, other than blood pressure and LDL-cholesterol control, remains important as the rate of diabetes increases worldwide. The accelerated atherosclerosis and cardiovascular disease in diabetes is likely to be multifactorial and therefore several therapeutic approaches can be considered. Results of mechanistic studies done in vitro and in vivo--animals and people--can provide important insights with the potential to improve clinical management decisions and outcomes. In this Review, we focus on three areas in which pathophysiological considerations could be particularly informative--ie, the roles of hyperglycaemia, diabetic dyslipidaemia (other than the control of LDL-cholesterol concentrations), and inflammation (including that in adipose tissue) in the acceleration of vascular injury.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18502305      PMCID: PMC2774464          DOI: 10.1016/S0140-6736(08)60768-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  127 in total

Review 1.  Signal integration in the endoplasmic reticulum unfolded protein response.

Authors:  David Ron; Peter Walter
Journal:  Nat Rev Mol Cell Biol       Date:  2007-07       Impact factor: 94.444

Review 2.  Advanced glycation end products (AGE) inhibit scavenger receptor class B type I-mediated reverse cholesterol transport: a new crossroad of AGE to cholesterol metabolism.

Authors:  Nobutaka Ohgami; Akira Miyazaki; Masakazu Sakai; Akihiko Kuniyasu; Hitoshi Nakayama; Seikoh Horiuchi
Journal:  J Atheroscler Thromb       Date:  2003       Impact factor: 4.928

3.  Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase.

Authors:  Ouliana Ziouzenkova; Stephane Perrey; Liana Asatryan; Juliana Hwang; Karen L MacNaul; David E Moller; Daniel J Rader; Alex Sevanian; Rudolf Zechner; Gerald Hoefler; Jorge Plutzky
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-26       Impact factor: 11.205

4.  Mechanisms involved in the stimulatory effect of advanced glycation end products on growth of rat aortic smooth muscle cells.

Authors:  N Seki; N Hashimoto; H Sano; S Horiuchi; K Yagui; H Makino; Y Saito
Journal:  Metabolism       Date:  2003-12       Impact factor: 8.694

5.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

Authors:  Rory Collins; Jane Armitage; Sarah Parish; Peter Sleigh; Richard Peto
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

Review 6.  The macrophage at the crossroads of insulin resistance and atherosclerosis.

Authors:  Chien-Ping Liang; Seongah Han; Takafumi Senokuchi; Alan R Tall
Journal:  Circ Res       Date:  2007-06-08       Impact factor: 17.367

7.  Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance.

Authors:  Justin I Odegaard; Roberto R Ricardo-Gonzalez; Matthew H Goforth; Christine R Morel; Vidya Subramanian; Lata Mukundan; Alex Red Eagle; Divya Vats; Frank Brombacher; Anthony W Ferrante; Ajay Chawla
Journal:  Nature       Date:  2007-05-21       Impact factor: 49.962

8.  Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones.

Authors:  Andrea L Hevener; Jerrold M Olefsky; Donna Reichart; M T Audrey Nguyen; Gautam Bandyopadyhay; Ho-Yin Leung; Matthew J Watt; Chris Benner; Mark A Febbraio; Anh-Khoi Nguyen; Brian Folian; Shankar Subramaniam; Frank J Gonzalez; Christopher K Glass; Mercedes Ricote
Journal:  J Clin Invest       Date:  2007-05-24       Impact factor: 14.808

9.  Retinaldehyde represses adipogenesis and diet-induced obesity.

Authors:  Ouliana Ziouzenkova; Gabriela Orasanu; Molly Sharlach; Taro E Akiyama; Joel P Berger; Jason Viereck; James A Hamilton; Guangwen Tang; Gregory G Dolnikowski; Silke Vogel; Gregg Duester; Jorge Plutzky
Journal:  Nat Med       Date:  2007-05-27       Impact factor: 53.440

Review 10.  Transcriptional control of apolipoprotein A-I gene expression in diabetes.

Authors:  Arshag D Mooradian; Michael J Haas; Norman C W Wong
Journal:  Diabetes       Date:  2004-03       Impact factor: 9.461

View more
  174 in total

1.  A novel role for epidermal growth factor receptor tyrosine kinase and its downstream endoplasmic reticulum stress in cardiac damage and microvascular dysfunction in type 1 diabetes mellitus.

Authors:  Maria Galán; Modar Kassan; Soo-Kyoung Choi; Megan Partyka; Mohamed Trebak; Daniel Henrion; Khalid Matrougui
Journal:  Hypertension       Date:  2012-06-04       Impact factor: 10.190

Review 2.  Vasoconstrictor prostanoids.

Authors:  Michel Félétou; Yu Huang; Paul M Vanhoutte
Journal:  Pflugers Arch       Date:  2010-03-24       Impact factor: 3.657

3.  Akt2 deficiency promotes cardiac induction of Rab4a and myocardial β-adrenergic hypersensitivity.

Authors:  Sharon Etzion; Yoram Etzion; Brian DeBosch; Peter A Crawford; Anthony J Muslin
Journal:  J Mol Cell Cardiol       Date:  2010-08-20       Impact factor: 5.000

4.  Comparative Efficacy and Safety of Laparoscopic Greater Curvature Plication and Laparoscopic Sleeve Gastrectomy: A Meta-analysis.

Authors:  Yu Tang; Shanhong Tang; Sanyuan Hu
Journal:  Obes Surg       Date:  2015-11       Impact factor: 4.129

5.  Soluble epoxide hydrolase inhibition improves coronary endothelial function and prevents the development of cardiac alterations in obese insulin-resistant mice.

Authors:  Clothilde Roche; Marie Besnier; Roméo Cassel; Najah Harouki; David Coquerel; Dominique Guerrot; Lionel Nicol; Emmanuelle Loizon; Isabelle Remy-Jouet; Christophe Morisseau; Paul Mulder; Antoine Ouvrard-Pascaud; Anne-Marie Madec; Vincent Richard; Jeremy Bellien
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-02-27       Impact factor: 4.733

6.  Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction.

Authors:  Tatiane M Murça; Patrícia L Moraes; Carolina A B Capuruço; Sérgio H S Santos; Marcos B Melo; Robson A S Santos; Vinayak Shenoy; Michael J Katovich; Mohan K Raizada; Anderson J Ferreira
Journal:  Regul Pept       Date:  2012-05-14

7.  Gender differences in the association of C-reactive protein with coronary artery calcium in type-2 diabetes.

Authors:  Atif N Qasim; Venkata Budharaju; Nehal N Mehta; Caitlin St Clair; Samira Farouk; Seth Braunstein; Mark Schutta; Nayyar Iqbal; Daniel J Rader; Muredach P Reilly
Journal:  Clin Endocrinol (Oxf)       Date:  2011-01       Impact factor: 3.478

8.  Intensive glucose lowering and cardiovascular disease prevention in diabetes: reconciling the recent clinical trial data.

Authors:  Theodore Mazzone
Journal:  Circulation       Date:  2010-11-23       Impact factor: 29.690

Review 9.  Update on the treatment of type 2 diabetes mellitus.

Authors:  Juan José Marín-Peñalver; Iciar Martín-Timón; Cristina Sevillano-Collantes; Francisco Javier Del Cañizo-Gómez
Journal:  World J Diabetes       Date:  2016-09-15

10.  Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians.

Authors:  Michel P Hermans; Jean-Charles Fruchart
Journal:  Ther Adv Chronic Dis       Date:  2011-09       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.